US 11,193,935 | Methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also, compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify and monitor various lung conditions. | Biodesix (Boulder, CO, USA) | Kearney PE, Fang KC, Li X-J, Hayward C | 12/7/2021 |
US 11,193,174 | Methods of detecting cancer in a patient that involve analyzing DNA in extracellular vesicles. Detection may involve screening for an insert in a 3′ UTR of NANOGP8 present in extracellular vesicles. | University of Central Florida Research Foundation (Orlando, FL, USA) | Sugaya K, Manjusha V | 12/7/2021 |
US 11,193,164 | Methods and compositions to detect, monitor and treat cancer that includes amplified extrachromosomal oncogenes. Methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells. | The Regents of the University of California (Oakland, CA, USA), Ludwig Institute for Cancer Research (Zurich, Switzerland) | Mischel P, Mali P, Bafna V, Turner K, Deshpande V, Beyter D | 12/7/2021 |
US 11,192,958 | Sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells, and the use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases. | Board of Regents, The University of Texas System (Austin, TX, USA) | Molldrem J, Sergeeva A | 12/7/2021 |
US 11,187,703 | A method of determining whether a subject has or is at risk of developing a cancer, comprising obtaining a sample from the subject; determining the levels of at least two target polypeptides, which are selected from the group consisting of ANXA2, HSPA5, KNG1 and MMP1; and assessing whether the subject has or is at risk of developing the cancer based on the levels of target polypeptides. Provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma. | S&T Biomed Co. Ltd. (Hsinchu, Taiwan) | Yu J-S, Chen Y-T, Chiang W-F, Hsiao Y-C, Chang Y-S, See L-C, Chang K-P | 11/30/2021 |
US 11,180,812 | Methods of diagnosing, determining a prognosis for, and monitoring cancer in a subject, involving selecting a subject having cancer and obtaining from the subject a sample containing exosomal DNA. The presence or absence of one or more mutations in BRAF and/or EGFR is detected in the exosomal DNA sample from the subject, and a diagnosis and/or prognosis of the cancer is given on the basis of the detection of the one or more mutations in BRAF and/or EGFR. | Cornell University (Ithaca, NY, USA), Sloan-Kettering Institute for Cancer Research (New York) | Lyden DC, Selgas HP, Zhang H, Bromberg J | 11/23/2021 |
US 11,180,557 | Compositions and therapeutic methods for activating an immune response in a patient in need thereof. The methods and compositions are able to antagonize the activity of VISTA, a naturally occurring ‘checkpoint’ protein that contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. | King’s College London (London), The Trustees of Dartmouth College (Hanover, NH, USA) | Noelle RJ | 11/23/2021 |
